Answers are grounded in this paper and cite their sources.
Anticancer drug development is becoming complex and demanding because humancancer leads to 12% of global human mortality. Chemical and pharmacological breakthroughsplay leading roles in updating drug evaluation and development for different types of tumors. Chemical and pharmacological breakthroughs manifest in different facets. A large proportion offinancial and workload increases in drug discovery must be paid off. In front of complexity,difficulties, and financial increase of drug development, evaluative promotion must go miniature-wise and single-cell-wise. Multi-omics knowledge and technology are greatly expandedand understood in depth. This type of technical trend is suitable for current experimental explorationand clinical occasions. Technical and pharmacologic advances are especially emphasizedto address this trend. Presently, the anticancer pharmaceutical study is multi-faceted and risk-taking. To keep up thismomentum, multi-disciplinary drug evaluation, clinical selection, and combination principlesshould be discovered. Past and futuristic chemical and pharmacological interactions and breakthroughsare discussed. In summary, the landscape of pharmaceutical investigation should be integrated with chemicaland pharmacological knowledge in every facet of drug development and clinical personalization.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2024) studied this question.
Synapse has enriched 7 related papers. Consider them for comparative context: